Insights
Search Results
Client Highlights
6.11.26
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
3.31.26
Wilson Sonsini Advises Insilico on Global R&D Collaboration with Lilly
On March 29, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
2.02.26
Wilson Sonsini Advises vTv on Expanded License Agreement with Newsoara
On February 2, 2026, vTv Therapeutics (vTv), a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases, announced that it has expanded its license agreement with Newsoara Biopharma providing the company with global rights to vTv's phosphodiesterase type 4 (PDE4) inhibitor, HPP737. Wilson Sonsini Goodrich & Rosati advised vTv on the transaction.
Client Highlights
11.13.25
Wilson Sonsini Advises Insilico on Research and Licensing Collaboration with Lilly
On November 10, 2025, Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (Lilly) where the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
Client Highlights
5.06.25
Wilson Sonsini Advises Stately Bio on $12 Million Seed Financing
On May 2, 2025, Stately Bio, a start-up developing cell therapies using an ML-powered live-cell imaging platform, emerged from stealth with $12 million in seed financing. The funding was led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health). The new funding will be used to scale the company’s platform technology and mature its internal pipeline of stem cell-derived therapeutics.
Client Highlights
11.14.24
Wilson Sonsini Advises LaNova Medicines on Exclusive Global License with Merck
On November 14, 2024, Merck and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that they entered into an exclusive global license for Merck to develop, manufacture, and commercialize LM-299, a novel investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF) that is currently in Phase 1 clinical trials in China. Wilson Sonsini Goodrich & Rosati advised LaNova on the transaction.
Client Highlights
9.26.24
Wilson Sonsini Advises Vertos Medical Inc. in Acquisition by Stryker
On August 22, 2024, Stryker, a global leader in medical technologies, announced a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Wilson Sonsini Goodrich & Rosati advised Vertos on the transaction.
Client Highlights
1.05.24
Wilson Sonsini Advises Insilico Medicine on License Agreement with Menarini Group
On January 4, 2024, Stemline Therapeutics, Inc. (Stemline), a wholly owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, announced they have entered into an exclusive licensing agreement granting Stemline global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico's AI platform as a potential treatment for hormone sensitive cancers and other oncology indications. Under the terms of the agreement, Stemline will pay to Insilico a $12 million upfront payment; potential development, regulatory, and commercial milestones in excess of $500 million; and royalties.
Client Highlights
10.12.23
Wilson Sonsini Advises BioMap on Strategic Collaboration with Sanofi
On October 10, 2023, BioMap, a disruptive life science AI company responsible for building the first and largest protein-centric large language model platform xTrimo, announced a strategic collaboration with Sanofi, a global healthcare and pharmaceutical company, to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform. Wilson Sonsini Goodrich & Rosati advised BioMap on the transaction.
Client Highlights
9.12.23
Wilson Sonsini Advises Insilico Medicine on $80 Million Agreement with Exelixis
On September 12, 2023, Exelixis, Inc. and Insilico Medicine announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds, in exchange for an upfront payment to Insilico of $80 million anticipated in the third quarter 2023. Insilico is also eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales.
Client Highlights
12.09.22
Firm Advises Arcellx on $4 Billion Collaboration with Kite
On December 9, 2022, clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop and commercialize Arcellx’s lead late-stage myeloma candidate. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.